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Xanthine oxidase inhibition for
the improvement of long-term
outcomes following ischaemic stroke
and transient ischaemic attack
(XILO-FIST) – Protocol for a
randomised double blind
placebo-controlled clinical trial
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Dickie1,4, Alex Doney5, Kirsten Forbes6, Graeme Houston7,
Sharon Kean8, Kennedy Lees1, Alex McConnachie8, Keith W
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Abstract
Background: Allopurinol, a xanthine oxidase inhibitor, reduced progression of carotid-intima media thickness and
lowered blood pressure in a small clinical trial in people with ischaemic stroke. Xanthine oxidase inhibition for improve-
ment of long-term outcomes following ischaemic stroke and transient ischaemic attack (XILO-FIST) aims to assess the
effect of allopurinol treatment on white matter hyperintensity progression and blood pressure after stroke. This paper
describes the XILO-FIST protocol.
Methods: XILO-FIST is a multicentre randomised double-blind, placebo-controlled, parallel group clinical trial funded
by the British Heart Foundation and the Stroke Association. The trial has been adopted by the Scottish Stroke Research
Network and the UK Clinical Research Network. The trial is registered in clinicaltrials.gov (registration number
NCT02122718). XILO-FIST will randomise 464 participants, aged greater than 50 years, with ischaemic stroke within
the past month, on a 1:1 basis, to two years treatment with allopurinol 300 mg twice daily or placebo. Participants will
undergo brain magnetic resonance imaging, cognitive assessment, ambulatory blood pressure monitoring and blood
sampling at baseline and after two years treatment. The primary outcome will be white matter hyperintensity progres-
sion, measured using the Rotterdam progression scale. Secondary outcomes will include change in white matter hyper-
intensity volume, mean day-time systolic blood pressure and measures of cognitive function. Up to 100 will undergo
additional cardiac magnetic resonance imaging in a sub-study of left ventricular mass.
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Discussion: If white matter hyperintensity progression is reduced, allopurinol could be an effective preventative
treatment for patients with ischaemic stroke and clinical endpoint studies would be needed. If allopurinol reduces
blood pressure after stroke, then it could be used to help patients reach blood pressure targets.
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Background
People who suffer an ischaemic stroke are at risk of
cognitive decline and recurrent vascular events.1–3
Guidelines recommend use of anti-thrombotic, blood
pressure (BP) lowering and lipid lowering agents to
reduce subsequent risk. These treatments reduce, but
do not eliminate, risk of recurrent stroke and other
vascular events and the effect of these treatments on
cognitive decline is unclear.4,5
Since white matter hyperintensities (WMHs) on brain
magnetic resonance imaging (MRI) are associated with
higher risk of recurrent stroke and cognitive decline,6 it
is hypothesised that these represent a biomarker of brain
ischaemic injury. WMHs are seen in as many as 90% of
people with ischaemic stroke,7,8 and the highest degrees
of WMH burden are associated with higher rates of
stroke, death and cognitive and physical decline.7,9
The burden of WMH often increases during longitudi-
nal follow-up and such increases are also associated
with increased incident stroke, dementia and cognitive
decline.6 Thus, treatments that reduce WMH progres-
sion could improve several outcomes after stroke includ-
ing cognition, functional outcome and recurrent stroke.
Allopurinol, a drug commonly prescribed for the
prophylaxis of gout, inhibits activity of xanthine oxi-
dase leading to reduction in both serum uric acid (UA)
and oxidative stress via reduced superoxide anion pro-
duction. Higher serum UA is associated with increased
risk of stroke,10 with adverse outcomes after ischaemic
stroke11,12 and with vascular cognitive impairment.
Allopurinol may deliver benefits independent of UA
reduction. In people with history of stroke, allopurinol
has been shown to reduce markers of inflammation,13
reduce augmentation index, reduce progression of
carotid intima-media thickness and lower BP14 and
has been shown to improve cerebral nitric oxide bio-
availability.15 Thus, allopurinol has a number of effects
on the vasculature, on both small and large cerebral
arteries, which may make it an effective drug for
stroke prevention. However, trials in people with
stroke have typically been small, of short duration,
and have not assessed progression of biomarkers of
cerebrovascular disease or clinical outcomes.
The xanthine oxidase inhibition for improvement of
long-term outcomes following ischaemic stroke and
transient ischaemic attack (XILO-FIST) trial is
designed to test whether allopurinol reduces the rate
of WMH progression and BP in people with recent
ischaemic stroke.
Methods/design
XILO-FIST is a randomised, double-blind, placebo-
controlled clinical trial of allopurinol 300 mg twice
daily vs. placebo in 464 people with recent ischaemic
stroke. The study is being conducted in stroke units in
the UK Clinical Research Networks. The trial includes
a sub-study of additional cardiac MRI in participants
with left ventricular hypertrophy (LVH) and some par-
ticipants also undergo carotid MRI.
Trial status
The first participant visit was in May 2015. As of 27
February 2018, the trial was open in 23 sites in the UK.
A total of 418 participants were enrolled and 354 par-
ticipants were randomised (with most of the remainder
in the trial run in phase). On average, 12 participants
per month are being randomised. One hundred and
eighty-eight participants have completed one-year
follow up; 57 participants have completed the two-
year follow-up. We aim to finish recruitment by
May 2018.
Ethical and regulatory approval
Ethics committee and regulatory approval has been
obtained for all participating sites (REC number
14/WS/0113). The trial is being conducted in accor-
dance with local regulations and UK law.
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Inclusion and exclusion criteria
Participants are aged greater than 50 years and have
suffered an ischaemic stroke or transient ischaemic
attack (TIA) with positive imaging within the past
four weeks. Ischaemic stroke and TIA are diagnosed
by a stroke specialist. Symptoms must last more than
24 h or for symptoms lasting less than 24 h (TIA), there
must be either a relevant diffusion-weighted imaging
(DWI) lesion on MRI or a corresponding lesion on
CT. The corresponding lesion on CT can include evi-
dence of cerebral small vessel disease. Full inclusion
and exclusion criteria are given in Table 1.
Participants with evidence of LVH on electrocardiog-
raphy (ECG, according to the Sokolow-Lyon or
Cornell voltage criteria) or on screening echocardiog-
raphy (defined as posterior or septal wall thickness of
>11 mm, or increased left ventricular mass (LVM)
defined as baseline LVM index of> 115 g/m2 (men)
or> 95 g/m2 (women), or LVM >162 g (men) or
>224 g (women)) and no current atrial fibrillation are
eligible for the cardiac sub-study.
Participant identification and recruitment
Potential participants are identified during in-patient
stay in an acute stroke unit or in a cerebrovascular
out-patient clinic. Eligibility is confirmed by a medical-
ly qualified investigator and participants must give
their own informed consent.
Study schedule
The study comprises a four-week run-in phase and a
104-week treatment phase. The detailed participant
schedule is shown in Table 2.
Run-in phase
The run-in phase comprises an enrolment visit on day 0
and a baseline assessment visit at four weeks. In order
to successfully complete the run-in phase, participants
must have had a medication review, completed baseline
data collection and completed brain MRI. Those who
do not successfully complete this phase are classed as
screen failures.
The baseline assessment visit includes a clinical eval-
uation (measurement of brachial sphygmomanometer
BP), blood tests for safety and biobanking (including a
blood test for serum UA to be centrally analysed),
a urine sample for biobanking, ambulatory blood
pressure monitoring (ABPM), ECG, brain MRI,
assessment of cognitive function and assessment of eli-
gibility for the cardiac sub-study (in participating sites
Table 1. Full inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Ischaemic stroke/ischaemic lesion on brain imag-
ing in relevant anatomical territory in patients
with transient ischaemic attack
Modified Rankin scale score of 5
Age greater than 50 Diagnosis of dementia
Consent within one month of stroke Cognitive impairment deemed sufficient to com-
promise capacity or comply with the protocol
Dependent on daily help from others for basic
activities prior to stroke
Significant co-morbidity or frailty likely to cause
death within 24 months
Contra-indication to or indication for adminis-
tration of allopurinol
Concurrent azathioprine, 6-mercaptopurine
therapy, other cytotoxic therapies, cyclosporin,
theophylline and didanosine
Significant hepatic impairment
eGFR< 30 ml/min
Contraindication to MRI scanning
Women of childbearing potential
Prisoners
Active participation in another CTIMP or device
trial or participation within the past month
eGFR< 60 and of Korean, Han Chinese or
Thai descent
MRI: magnetic resonance imaging; eGFR: estimated glomerular filtration rate; CTIMP: Clinical trial of investigational medici-
nal product.
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only). In sites with experience of carotid plaque MRI,
carotid MRI will be performed after the brain
MRI scan.
Randomisation is performed following successful
completion of the run-in phase. Study medication
then starts.
The treatment phase
Week 4 visit: Brachial sphygmomanometer BP is mea-
sured, safety bloods are taken, participants are asked
regarding adverse events (AEs) and an ABPM is per-
formed. Dose of study drug is increased at this visit if
the criteria are met for dose escalation.
Week 13/26/52/78 visit: Brachial BP is measured,
safety bloods are taken (except at week 78), partici-
pants are asked regarding AEs and an ABPM is per-
formed. A Montreal Cognitive Assessment (MoCA) is
also performed at week 52.
Week 104 visit: Brachial BP is measured, safety
bloods and bloods for biobanking are taken, partici-
pants are asked regarding AEs and an ABPM is per-
formed. Brain MRI and cognitive testing are repeated.
Participants in the cardiac sub-study undergo an
additional cardiac MRI. A further assessment for seri-
ous AEs (SAEs) is made at week 105 by telephone.
Randomisation
Participants are randomised (1:1) to receive either allo-
purinol or placebo orally for 104 weeks. Randomisation
codes are stored securely on the Robertson Centre for
Biostatistics (RCB, University of Glasgow) network,
with restricted access. Eighty per cent of participants
are allocated to treatments by a minimisation algorithm
which includes presence of WMH at baseline and sub-
study eligibility as minimisation factors, Randomisation
carried out via the study web portal. A telephone inter-
active voice response system is available as a backup.
Intervention
Participants receive either allopurinol 300 mg or place-
bo twice daily for two years. During the first four
weeks, a single 300 mg daily dose of allopurinol or
placebo is taken. All participants then undergo dose
titration to allopurinol 300 mg twice daily or placebo
unless creatinine clearance (estimated via estimated
glomerular filtration rate (eGFR)) is< 60 mL/min
Table 2. Participant schedule.
Activity
Run-in phase Treatment phase
Day
0
Week
4
Week
0
Week
4
Week
13
Week
26
Week
52
Week
78
Week
104
Review eligibility  
Informed consent 
Optimise preventative therapy 
Clinical evaluationa       
Safety blood testsb       
Blood for uric acid level  
Blood/urine for biobanking  
ECG  
Echocardiography 
Determine cardiac sub-study eligibility 
MRI brain ( carotid MRI)  
ABPM   
Cardiac MRI,c n¼100  
Detailed cognitive function evaluation  
Assessment of run in completion 
Randomisation 
Dispense      
Return/count IMP      
Adverse event review       
Note that the run in week 4 and treatment phase week 0 visits can take place concurrently. Participants will also be contacted by telephone at week
105, which marks the end of the study.
IMP: investigational medicinal product; ABPM: ambulatory blood pressure monitoring; ECG: electrocardiography; MRI: magnetic resonance imaging.
aMeasures of stroke severity at week 4, modified Rankin scale score and MoCA at week 52 and blood pressure at all visits except week 78 and weight
at week 104).
bFBC, Uþ E, LFTs.
cSub-study eligible participants only.
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where once daily dosing is continued. Dose modifica-
tion (a reduction from 300 mg twice daily to 300 mg
once daily) occurs if renal function declines (to an
eGFR of< 50 mL/min) or in the event of side effects.
Dosing is stopped if renal function declines to an
eGFR of< 30 mL/min. After the 104-week assessment,
treatment with study medication stops.
Blinding
The study is double blind. An identical placebo is used.
Changes in UA levels could compromise allocation
concealment and these are not to be checked during
the study. Unblinding should only occur in emergency
situations where knowledge of the investigational
product assignment is essential for the care of the par-
ticipant. All investigators have received training in
unblinding procedures.
Brain and carotid MRI
Brain MRI is performed using 1.5 or 3T MRI, and in
each individual, the same scanner should be used for
baseline and follow-up. Study sequences include
T1-weighted imaging, T2-weighted imaging and T2
fluid attenuation inversion recovery (FLAIR), DWI
and susceptibility weighted imaging. Isotropic T1, T2
and FLAIR imaging will be performed where possible
(Table 3). Carotid MRI imaging includes time of flight
carotid angiography, black blood T1, black blood T2
and black blood proton density imaging of the carot-
id arteries.
Assessment of WMH
The STRIVE recommendations are followed during
image review.16 WMH of presumed vascular origin
are defined as hyperintense lesions on T2-FLAIR and
can appear as isointense or hypointense (although
often not as hypointense as CSF) on T1-weighted
sequences. All scans are reviewed blinded to treatment
allocation.
A Fazekas and Scheltens scales is assigned.17,18
The Rotterdam progression score (RPS) and
Schmidt’s progression score are calculated by simulta-
neous review of the baseline and two-year scans.19,20
All visual rating scales are assessed independently by
two trained observers. Where there is any level of dis-
agreement on a score, that score will be reviewed by at
least two raters and a consensus score applied.
Volumetric assessment of WMH volume will also
be performed. The first step in automated extraction
of WMH volumes is to estimate the white matter
area in each subject using atlas-based segmentation.21
A probability map of white matter created from 313
volunteers aged 18–96 years is used,22 and this map is
registered to each subject using non-linear (diffeomor-
phic) registration to provide an initial estimate of
white matter in each subject.21 Hyperintense outliers
are identified on T2 FLAIR by transforming each
voxel to a standard (z) score. Voxels with z  1.5 and
within the estimated white matter area are initially
defined as WMH. Final WMH estimates are defined
by 3D Gaussian smoothing to reduce noise and
account for partial volumes around WMH edges.
Automatic WMH estimates are visually checked and
infarcts masked by a trained image analyst following
Table 3. Sequence parameters used for brain and carotid imaging in co-ordinating centre and on Siemens PRISMA 3T system.
Scan Sequence Orientation TE TR TI
Slice
Thickness
Slice
gap Matrix FOV
Slice
number
Total
time
Brain
T1 TFL SAG 1.85 2000 900 1.0 50% 256 100 255 176 4.4
T2 SPC TRA 404 3000 – 0.9 – 256 100 230 176 5.32
FLAIR SPCIR SAG 397 5000 1800 1.0 – 256 100 255 160 4.02
DWI RESOLVE TRA 62 4100 – 4 30% 224 100 220 27 3.55
SWI SWI_r TRA 20 24 – 1.5 20% 256 95 230 96 4.45
DTI EPSE TRA 95 3600 – 4 30% 128 100 230 30 2.51
ASL EPFID TRA 11 3500 – 6 16% 64 100 255 20 6.06
Carotids
TOF FL_r TRA 3.11 20 – 1.0 – 384 75 200 32/3 slabs 2.57
T1 tse TRA 17 740 – 2.0 50–200% 256 100% 140 5 to 11 2.37
T2 tse TRA 79 740 – 2.0 50–200% 192 100% 140 5–11 1.51
PD tse TRA 16 740 – 2.0 50–200% 192 100% 140 5–11 1.51
FLAIR: fluid attenuation inversion recovery; DWI: diffusion weighted imaging; SWI: susceptibility weighted imaging; DTI: diffusion tensor imaging. ASL:
arterial spin labelling. FOV: field of view, TRA: transverse; SAG: sagittal; TOF: time of flight; PD: proton density; TE: echo time; TR: repitition time; TI:
inversion time.
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STRIVE guidelines.16 Normal-appearing tissues
including cortical grey matter, sub cortical grey
matter, cerebral white matter and supratentorial cere-
brospinal fluid are segmented using population-specific
tissue probability maps, within-patient T1 intensity
data, and adjoining voxel data.23,24 Normal-appearing
tissue segmentations are checked and edited in the same
manner as WMH.
Cardiac sub-study
Participants in the sub-study undergo additional cardi-
ac 3T MRI at baseline and two years.
ABPM
Twenty four-hour ABPM is performed at baseline,
week 4 and week 104 unless contraindicated. A
Spacelabs Ultralight Ambulatory Blood Pressure
Monitor is used. This is set to take readings every
30min during daytime (08:00 h–21:59 h) and every
60min during night-time (22:00 h–07:59 h). ABPM
data will not be performed in some participants with
significant arm weakness due to safety concerns.
Cognitive and quality of life measures
The assessment of pre-stroke cognitive impairment
uses the 16-item IQCODE.25 A score of 3.6 or
greater is used as threshold to define probable pre-
stroke dementia.
A comprehensive cognitive examination will be per-
formed at baseline and at the two-year follow-up.
The battery comprises: the MoCA; Animal Naming
test of semantic fluency; Controlled Oral Word
Association Test; Letter Digit Coding Test; Hopkins
Verbal Learning Test; Centre for Epidemiological
Studies – Depression Scale (CES-D); neuropsychiatric
inventory questionnaire version (final follow-up visit
only) and a trail making test. The EQ-5D and the
Stroke Impact Scale Short Form26 are also measured.
The battery is administered by a trained assessor,
scored to pre-specified marking sheets and are
conducted in a standardised fashion. Participants
are free to take breaks as needed. If participants are
unable to complete the full battery, the assessor prioritises
the MoCA and CES-D. Details of each of these scales are
given in a detailed instruction booklet, which includes
instructions for administering each assessment.
Safety blood tests and pharmacovigilance
Safety blood tests including a full blood count, urea
and electrolytes and liver function tests are checked
at all study visits with the exception of the week 78
visit. Blood for serum UA levels is obtained at the
end of the run-in phase (baseline visit) and at week
104 during the treatment phase. Serum UA levels will
be measured centrally.
Predictable side effects of the investigation medicinal
product (IMP) used in this trial (allopurinol) are referred
to in the summary of medicinal product characteristics
(SmPC). All SAEs occurring within the first 13 weeks of
the treatment phase will be recorded and reported to the
Sponsor. Thereafter and up to 30 days after completing
the study, unexpected SAEs, suspected unexpected seri-
ous adverse reactions and events of special interest that
meet criteria for an SAE will be reported.
Criteria for stopping study medication and
study withdrawal
Participants developing a rash, fever, liver dysfunction
(defined as bilirubin or transaminase levels increasing
to three times the ULN), renal dysfunction (defined as
a drop in eGFR to below 30 mL/min), eosinophilia
(defined as an eosinophil count of> 0.45 109 or a
fall in haemoglobin below 10 g/dL or neutrophil
count of <1.5 109 on any blood sample of a platelet
count of <50 109 that is not due to clumping cease
taking study medication immediately and permanently
if no alternative cause is found. We will not recruit
additional participants to replace those who stop treat-
ment and participants who withdraw from treatment
will be asked to remain under follow-up.
Study outcomes
The primary outcome is WMH progression measured
using the RPS. Secondary outcomes and exploratory
outcomes are shown in Table 4. The primary outcome
in the cardiac sub-study is LVM index.
Statistical analysis
Full details of all statistical issues and planned statistical
analyses will be specified in a separate statistical analysis
plan which will be agreed before database lock and
unblinding of treatment codes to the study statisticians.
All data will be summarised overall and by treat-
ment group. Efficacy analyses will be carried out
according to the intention-to-treat (ITT) principle,
that is, in relation to randomised treatment allocation,
regardless of treatments actually received. The popula-
tion for ITT analyses will be all validly randomised
participants, who do not have any major protocol vio-
lations. Additional analyses will be carried out using a
per-protocol (PP) population, consisting of those mem-
bers of the ITT population who remain on treatment as
randomised and do not have any minor protocol vio-
lations. All protocol violations will be assessed and
classified as major or minor, prior to database lock.
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Unadjusted between-group comparisons of continu-
ous and ordinal outcomes will be made using t-tests or
Wilcoxon-Mann-Whitney tests as appropriate; categor-
ical outcomes will be compared using Fisher’s exact
tests. Adjusted analyses will use regression models,
adjusted for variables used in the minimisation algo-
rithm. Distributional assumptions will be assessed visu-
ally and where necessary, outcomes will be
transformed, or a generalised linear model will be
used with appropriate link and variance function. The
model to be used for each outcome will be decided and
documented prior to database lock. Treatment effect
estimates will be reported with 95% confidence inter-
vals and p-values.
Analysis of primary outcome – WMH progression is
not expected to follow a normal distribution.
Unadjusted comparison of treatment groups will use
a Wilcoxon-Mann-Whitney test. A generalised linear
regression model, with appropriate link and variance
function, will be used to model WMH progression in
relation to treatment and variables used in the minimi-
sation algorithm. A further model will be fitted adjust-
ing for other baseline characteristics found to be
associated with WMH progression during blinded
analyses, prior to database lock.
This model will be extended to assess the mediating
effects of other study outcomes, such as changes in BP
and UA post-randomisation.
Analysis of secondary outcomes – secondary efficacy
outcomes will be analysed using appropriate two-
sample tests followed by regression analyses to estimate
between-group differences adjusted for variables used
in the minimisation algorithm. For outcome measures
recorded at baseline as well as at follow-up, regression
models will be adjusted for the baseline value. For
endpoints measured at several time points, each time
point will first be analysed separately, and then a
repeated measures model will be applied to model
measurements at all time points simultaneously.
Planned subgroup analyses – the moderating effects
of baseline UA level in the primary analysis will be
assessed through use of interaction terms in the
model. These methods will also be used to investigate
the moderating effects of other baseline characteristics
in an exploratory manner.
Sample size
We assumed that 90% of participants would have evi-
dence of WMH at baseline and that, over two years,
approximately 64% would progress by one point or
Table 4. Primary, secondary and exploratory outcomes.
Primary outcome Secondary outcomes Exploratory outcomes
Rotterdam progression scale Change in mean day-time systolic BP at
one month
Fazekas’ score
Change in mean day-time diastolic BP at
one month
Schelten’s scale score
Schmidt’s progression score Measures of BP variability
WMH volume at two years One month mean day-time diastolic
blood pressure
Fazekas’ score at two years Two-year mean day-time diastolic BP
Schelten’s scale score at two years Clinic brachial BP
New brain infarction on MRI Incident atrial fibrillation
Rotterdam progression score with those
who die/become too frail to undergo
repeat imaging assigned worst score
Recurrent stroke
MoCA score Recurrent myocardial infarction, stroke or
cardiac death
Change in mean day-time systolic BP at
two years
Hospitalisation for, or incident heart failure
Change in mean day-time diastolic BP at
two years
Incident dementia
Mortality
Animal naming test
Controlled word association test
Hopkins verbal learning test
Trail making test
Quality of life (EQ-5D, SS-QOL)
Modified Rankin scale score
BP: blood pressure; MoCA: Montreal cognitive assessment.
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more on the RPS and that the mean progression score
in the placebo group will be 1.293. This and the pro-
gression rate seen with a 30% reduction in WMH pro-
gression score are shown in Table 3. Based on a
Wilcoxon-Mann-Whitney test, a sample size of 192
participants per group would give 80% power to
detect this difference at a 5% significance level
(nQuery AdvisorVR v7.0). This treatment effect is sub-
stantially less than the 80% relative reduction seen in
the PROGRESS MRI study.17
Although we will minimise loss to clinical follow-up
(completed for all except one participant in our pilot
study), we have increased sample size to account for a
10% drop out rate seen in our pilot study and by an
additional small amount to account for the fact that
those with no WMH at baseline may progress at a
lower rate. We will thus randomise 232 participants
per group (10% drop outs will give data on 209 partic-
ipants giving a further 17 participants (8%) per group
to ensure sufficient power).
Other sample size calculations were based on two-
sample t-tests. For ABPM, 101 participants per group
will be required to give 80% power at a 5% significance
level to verify the 3.3 mmHg reduction in systolic BP
(SBP) seen in the recent meta-analysis18 (assumed SD
of change in SBP 8.3). For the cardiac sub study, 25
participants per group would give 80% power to detect
a 3.7 g difference in LV mass (assumed standard devi-
ation 4.6). A 3.86 g difference was seen in a recent trial
of allopurinol use in patients with type 2 diabetes.
Trial and data management
All study data will be held in the study Robertson
Centre for Biostatistics, University of Glasgow, part
of the UKCRC-registered Glasgow Clinical Trial
Unit (number 16). A secure and restricted electronic
data capture system (electronic case report form) will
be used.
A Trial Management Group (TMG) meets regularly
during the study.
Trial steering and data monitoring committees. A Trial
Steering Committee meets at least annually and com-
prises an independent chair, three other independent
members, a participant and/or a carer representative,
the chief investigator and statistician. An independent
data monitoring committee (IDMC) meets at least
annually. This comprises of four independent mem-
bers. Only the IDMC has access to unblinded outcome
data before the trial ends.
Summary and conclusion
XILO-FIST is designed to test whether allopurinol
reduces the rate of WMH progression and BP in par-
ticipants with recent ischaemic stroke. The hypothesis
underlying XILO-FIST is that UA reduction and xan-
thine oxidase inhibition will improve vascular health
and lower BP leading to a reduction in progression of
WMH progression on MRI. If WMH progression is
reduced, allopurinol could be an effective preventative
treatment for people with ischaemic stroke and clinical
endpoint studies would be needed. If allopurinol
reduces BP after stroke, then it could be used to help
people reach BP targets.
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